Viking Therapeutics (VKTX) Enterprise Value (2016 - 2026)
Viking Therapeutics (VKTX) has disclosed Enterprise Value for 13 consecutive years, with -$603.0 million as the latest value for Q1 2026.
- For Q1 2026, Enterprise Value rose 29.22% year-over-year to -$603.0 million; the TTM value through Mar 2026 reached -$603.0 million, up 29.22%, while the annual FY2025 figure was -$705.7 million, 21.81% up from the prior year.
- Enterprise Value hit -$603.0 million in Q1 2026 for Viking Therapeutics, up from -$705.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$135.7 million in Q1 2023 and bottomed at -$963.0 million in Q1 2024.
- Average Enterprise Value over 5 years is -$567.9 million, with a median of -$603.0 million recorded in 2026.
- Year-over-year, Enterprise Value surged 61.35% in 2023 and then crashed 609.82% in 2024.
- Viking Therapeutics' Enterprise Value stood at -$155.5 million in 2022, then tumbled by 132.87% to -$362.1 million in 2023, then plummeted by 149.29% to -$902.6 million in 2024, then grew by 21.81% to -$705.7 million in 2025, then grew by 14.56% to -$603.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$603.0 million, -$705.7 million, and -$714.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.